In order to establish a robust biomarker in this clinical setting, prospective studies are needed to determine the clinical performance of CTLA4 promoter hypomethylation as a predictive biomarker for ICB in patients with ccRCC. This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.